The results of a survey released on 1 March 2021 by independent pollster Levada-Centre (Levada) indicate that over 60% of Russians said they are not ready to get a shot of the Russian Sputnik V COVID-19 vaccine, CNN reported on Tuesday.
According to Levada, which conducted the poll in late February 2021 and queried 1,601 people in 50 regions via in-person interviews, 62% of Russians surveyed said they don't want to be vaccinated with Sputnik V. Only 30% said they would, as compared to 38% in December 2020.
The main reasons stated by respondents against getting the vaccine were concerns over side effects (37% of those not ready for vaccination) or wanting to wait until the trials are complete (23%).
Another 16% of respondents said they "don't see any point" in getting vaccinated. In December 2020, fewer people feared side effects (29%) and more were waiting for the trials to finish (30%).
This survey also found that 64% of people thought the theory that COVID-19 was created artificially as a biological weapon was more probable than its natural origin, which only 23% believed.
Reportedly, the origins of COVID-19 became highly politicised in 2020 and many conspiracy theories have arisen in the US, Russia and elsewhere about the origins of the virus in humans.
The World Health Organisation team that went to Wuhan, China in February 2021 to explore the origins of COVID-19 said the version that the virus emerged from a lab is highly unlikely and is not being investigated further.
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Zoetis announces EU approval for Portela to relieve osteoarthritis pain in cats
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
GC Biopharma granted CMO rights for Curevo Vaccine's shingles vaccine
TransCode acquires Polynoma and secures USD25m investment from CK Life Sciences
Wasatch BioLabs adds three Oxford Nanopore-developed research-use-only assays to service portfolio
GSK and IQVIA expand vaccine track with local data to drive targeted public health action